English
Regional settings| Spread | 0.35 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ HK$5,000.00 Short position overnight fee ~ HK$4,000.00 | -0.022639% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ HK$5,000.00 Short position overnight fee ~ HK$4,000.00 | 0.000721% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | HKD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | Hong Kong | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 6.3 |
| Open | 6.3 |
| 1-Year Change | -19.23% |
| Day's Range | 6.3 - 6.55 |
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.
BRIEF: For the fiscal year ended 31 December 2021, CSPC Pharmaceutical Group Ltd revenues increased 12% to RMB27.87B. Net income increased 9% to RMB5.61B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was partially offset by Selling and distribution expenses increase of 11% to RMB10.44B (expense), Research and development expenses increase of 19% to RMB3.43B (expense).
